Perissutti E, Fiorino F, Severino B, Frecentese F, Massarelli P, Nencini C, Santagada V, Caliendo G
Dipartimento di Chimica Farmaceutica e Tossicologica1, Università di Napoli Federico II, Napoli, Italy.
Pharmazie. 2007 Jun;62(6):403-5.
Galanthamine is an alkaloid approved for the treatment of Alzheimer's disease. In this paper the syntheses and the anticholinesterase activities of new glucosyl and nitroxy derivatives substituted on position 6 are reported. Compounds 2, 3 and 5 presented a percentage of inhibition of 35.22%, 47.48% and 67.89% respectively.
加兰他敏是一种被批准用于治疗阿尔茨海默病的生物碱。本文报道了在6位上取代的新型葡萄糖基和硝氧基衍生物的合成及其抗胆碱酯酶活性。化合物2、3和5的抑制率分别为35.22%、47.48%和67.89%。